Press Release: Sarclisa approved in the US as the first anti ... - Sanofi
WEB2 days ago · Brian Foard Executive Vice President, Head of Specialty Care, Sanofi “Since first launching in 2020, we have made significant progress towards our ambition of establishing Sarclisa as a best-in-class therapy. The FDA’s decision marks another momentous milestone toward our goal and expands the reach of this potentially transformative therapy ...
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Press Room - Sanofi US News
WEB3 days ago · SARCLISA (isatuximab-irfc) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Room - Sanofi US News
WEBAug 8, 2024 · Sarclisa (isatuximab) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple …
WEB3 hours ago · Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple …
WEB6 hours ago · On Saturday, the FDA approved Sanofi’s SA (NASDAQ:SNY) Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult ...
Press Release: Sarclisa accepted for FDA priority review for ... - Sanofi
WEBMay 27, 2005 · Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma. FDA Priority Review granted based on positive results from IMROZ phase 3 study. If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care …
Press Release: Sarclisa induction treatment demonstrated ... - Sanofi
WEBAug 8, 2005 · Sarclisa (isatuximab) in combination with standard-of-care lenalidomide, bortezomib, and dexamethasone (RVd) during 18-week induction treatment followed by transplant resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared to RVd induction therapy, …
Sanofi wins US approval for multiple myeloma drug in newly …
WEB2 days ago · Sept 20 - The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's (SASY.PA) Sarclisa infusion as a treatment for certain types of ...
Press Release: Sarclisa approved in the US as the first anti
WEB2 days ago · Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six ...
- Some results have been removed
Skip to content